Skip to main content
. 2021 Apr 21;4(4):e215845. doi: 10.1001/jamanetworkopen.2021.5845

Figure 2. Hypothetical Outcomes in LRRK2-Targeted Therapies in Different Genetic Groups.

Figure 2.

After disease onset, in the case that GBA mutations are benign in LRRK2 Parkinson disease (PD), according to an inert hypothesis for LRRK2/GBA carriers, treatment responses for effective LRRK2-targeting therapies would be identical for carriers of LRRK2 and LRRK2/GBA carriers. Alternatively, in the masked hypothesis for carriers of LRRK2/GBA, LRRK2 variations are biologically masking the effects of GBA variations in disease progression, and LRRK2-targeting therapy would unmask the effects of GBA variations to match disease progression and cognitive decline associated with GBA variations.